Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world effectiveness of house dust mite sublingual immunotherapy tablets in allergic rhinitis
jRCT1030240168Completed
- Sponsor
- Torii Pharmaceutical
- Start
- Jun 2024
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of standardized house dust mite extract in allergic rhinitis (AR) (2 cohorts), sponsored by Torii Pharmaceutical. Primary endpoints: Number of patients with at least one symptom-relieving allergic rhinitis prescription by each follow-up year, Number of total symptom-relieving allergic rhinitis prescriptions by each follow-up year and 1 more. Started Jun 2024; status: completed.
02
Drugs
standardized house dust mite extract
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on jRCT1030240168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1030240168.